How Will the Market React to Hoth Therapeutics Inc (HOTH) Stock Getting a Bearish Rating

The market has been down on Hoth Therapeutics Inc (HOTH) stock recently. HOTH gets a Bearish score from InvestorsObserver Stock Sentiment Indicator.

Hoth Therapeutics Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on HOTH!

See Full HOTH Report

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With HOTH Stock Today?

Hoth Therapeutics Inc (HOTH) stock is trading at $3.01 as of 10:02 AM on Wednesday, Jun 14, a gain of $0.02, or 0.64% from the previous closing price of $2.99. The stock has traded between $2.94 and $3.06 so far today. Volume today is light. So far 516,294 shares have traded compared to average volume of 3,740,867 shares. To screen for more stocks like Hoth Therapeutics Inc click here.

More About Hoth Therapeutics Inc

Hoth Therapeutics Inc is a development-stage biopharmaceutical company. It is focused on targeted therapeutics for patients suffering from conditions such as atopic dermatitis, also known as eczema, chronic wounds, psoriasis, asthma, and acne. The company owns the BioLexa Platform which combines an FDA-approved zinc chelator with one or more approved antibiotics in a topical dosage form to address unchecked eczema flare-ups. Click Here to get the full Stock Report for Hoth Therapeutics Inc stock.